Placenta Extract on Liver: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Liu-Hong Shen.

The placenta contains multiple biologically active substances, which exert antioxidation, anti-inflammatory, immunomodulatory, and delayed aging effects. Its extract can improve hepatic morphology and function: on the one hand, it can reduce liver interstitial collagen deposition, lipogenesis, and inflammatory cell infiltration and improve fibrosis; on the other hand, it can prevent hepatocellular degeneration by scavenging reactive oxygen species (ROS) and inhibiting inflammatory cytokine production, further improve hepatocyte apoptosis and necrosis, and promote hepatocyte regeneration, making it a promising liver-protective agent.

  • placenta extract
  • liver injury
  • oxidative stress
  • liver inflammation

1. PE Improves Liver Histological Structures

The histological structures are the most intuitive indicators to evaluate the liver health status. PE has been reported to possess hepatoprotective effects against chemical factors (drugs, alcohol) [42[1][2][3],62,63], physical factors (partial hepatectomy) [64][4], and nutritional disorders (methionine and choline deficiency, high salt intake) that induce liver histological structure damage [50,65][5][6]. For example, PE could improve the vacuolar degeneration and steatosis of hepatocytes [42,51,64][1][4][7], inhibit the process of hepatocyte apoptosis and necrosis [51[7][8],66], and restore normal cellularity, including a typical polygonal morphology, normal cytoplasm and nucleus, and clear cell edges [62][2]. For the interstitial changes in the liver, PE reduces the dilatation and congestion of hepatic sinusoids and central veins and inhibits lipogenesis and inflammatory cell infiltration [62][2]. Further, PE attenuates the proliferation of fibrosis tissue, collagen, and fat deposition in the damaged liver [65,67][6][9] and inhibits pseudolobule formation [64][4], ultimately alleviating liver fibrosis and the fatty liver process [42,50,68][1][5][10]. In addition, a hepatoprotective agent with the placenta as the adjuvant and the transplantation of chorionic plate-derived mesenchymal stem cells (CP-MSCs) can also reduce hepatocyte necrosis, inflammatory cell infiltration, and collagen and fat deposition [63][3]. Transplantation of chorionic plate-derived mesenchymal stem cells (CP-MSCs) can also reduce inflammatory cell infiltration, improve liver collagen and fat deposition, and further reduce liver fibrosis and cirrhosis [67][9]. In summary, PE shows excellent hepatoprotection toward liver histological structures exposed to the above pathogenic factors.

2. PE Improves Liver Function

Liver function is canonically measured by several enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), and leucine aminopeptidase (LAP). In particular, lactic dehydrogenase (LDH) is a widely accepted indicator of liver injury. In addition, serum total protein (TP), liver glycogen, bile secretion, and the metabolic capacity of the liver to indocyanine green (ICG), bilirubin (BIL), fat, and alcohol can also be used to assess the severity of liver injury [69,70,71,72][11][12][13][14]. On the one hand, PE decreases the serum levels of ALT, AST, ALP, GGT, LDH [51,62,68,73,74,75,76,77,78][2][7][10][15][16][17][18][19][20], total bilirubin (TBIL), cholesterol (CHOL), triglyceride (TG), and non-esterified fatty acid (NEFA), and increases hepatic phospholipid and serum TP levels [62,64,66,79][2][4][8][21]. On the other hand, PE enhances the metabolic actions of the liver to bromosulfalein (BSP), iron, and alcohol, such as facilitating the scavenging of BSP and alcohol, decreasing hepatic iron deposition, and recovering the urine iron concentration [52,53,80][22][23][24]. Bile promotes the digestion and absorption of fat and fat-soluble vitamins secreted by hepatocytes. PE facilitates hepatic bile secretion by promoting sphincter movement and gallbladder contraction [52,53][22][23]. Moreover, PE supplementation decreases exercise-induced serum lactate elevation, increases hepatic glycogen content [74][16], alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) activity, and decreases the area under the curve (AUC) and the maximal concentration (Cmax) of alcohol [73][15]. However, the level of LDH increased in serum after administering PE in a report on alcohol-induced liver injury. The reason is that LDH is widely distributed in all organs, especially in the heart, liver, and muscle. After a single administration of ethanol and PE, the level of LDH in serum cannot change significantly, and the elevation of LDH might indicate liver diseases, malignancies, heart diseases, and hematological diseases [73][15].
In addition, a hepatoprotective agent with the placenta as an adjuvant can also reduce ALT, AST, ALP, and TBIL levels in serum [63][3]. After CP-MSC transplantation in the liver, the ICG metabolism increased and returned to normal levels, and TBIL levels decreased [67][9]. The placenta-derived stem cells (PDSCs) uptake ICG, store glucose as glycogen, and generate urea [81][25]. These effects are observed either by pretreatment or incubation with PE over the entire culture period, which indicates that PE could promote PDSCs’ differentiation into hepatocytes and exhibit some hepatocellular functions. In a study, the intravenous administration of PE was superior to subcutaneous administration, which was related to drug adsorption speculatively [66][8]. Interestingly, PE had different effects on AST in freshly isolated and primary cultured hepatocytes. The former increased while the latter decreased [82][26], possibly because the isolated hepatocyte membrane was damaged, and due to the additional effect of PE on the membrane; moreover, the therapeutic effect of PE is attenuated after pasteurization [68][10], presumably due to the inactivation of some components by high temperatures. In conclusion, PE can improve liver function by reducing liver enzyme levels and restoring the liver metabolism, synthesis, and secretion functions of BIL, fat, and alcohol.

3. PE Improves Liver Oxidative Stress

PE contains various antioxidant components, such as uracil, L-tyrosine, L-phenylalanine, L-tryptophan, and collagen peptides. Among them, the antioxidant activity of the mixture of uracil, L-tyrosine, and L-phenylalanine accounts for around 46% of PE, and it can effectively scavenge free radicals and decrease the malondialdehyde (MDA) level [14][27]. The antioxidant activity of collagen peptide accounts for around 15% of PE, and it can degrade deoxyribose and scavenge free radicals [15][28]. L-tryptophan exerts a potent free radical scavenging effect by inhibiting the lipid peroxidation induced by oxidative stress, and its antioxidant activity is even higher than the mixture of uracil, L-tyrosine, and L-phenylalanine mentioned above [14,16][27][29].
Multiple pathogenic factors cause an increase in ROS production, which leads to OS and hepatocellular injury. For this reason, there are a variety of antioxidant systems, especially antioxidant enzymes, in the body. The critical antioxidant systems include glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and catalase (CAT), which are said to be the body’s first line of defense against ROS [83][30]. Furthermore, there are particularly high concentrations of glutathione (GSH) in the liver, which buffers the redox equilibrium of the cell by undergoing oxidation or reduction reactions, according to the redox potential of the cell [84][31]. In addition, phase II detoxification enzymes, including heme oxygenase-1 (HO-1) and quinone oxidoreductase 1 (NQO1), are involved in detoxifying OS. HO-1 regulates the balance between free heme and bound heme to prevent the accumulation of free heme, which is essential to avert heme toxicity. Moreover, HO-1 suppresses the generation of ROS by downregulating several components of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-4 (NOX-4), including p22 phox and p67 phox [50,85][5][32]. NQO1 is known to maintain alpha-tocopherol (vitamin E) and coenzyme Q10 in their reduced antioxidant state, making it an even more potent antioxidant to protect cells against OS [86][33]. The above antioxidants work together to exert antioxidant effects and maintain an oxidant–antioxidant status balance in the body.

34. PE Improves Liver Inflammation

Inflammation is an adaptive response triggered by foreign pathogens or tissue injury and involves many complex interactions between cellular and inflammatory mediators, closely associated with OS and liver fibrosis [89][34]. Supplementation of PE reduces the accumulation of macrophages and decreases the concentrations of inflammatory biomarkers, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, and IL-10 [50,51,53,62,74,75,88][2][5][7][16][17][23][35]. Furthermore, PE increases serum interferon-gamma (IFN-γ) [74][16] and immunoglobulin G2a (IgG2a) [88][35] levels, which suggests that PE could enhance the body’s immune function. Intercellular adhesion molecule-1 (ICAM-1) is an important adhesion molecule that mediates the adhesion reaction and leukocyte migration, usually used as an indicator of inflammation [90][36]. PE decreases the mRNA and protein expression of ICAM-1 and inhibits the interaction of hepatocytes with lymphocytes [75][17]. Moreover, immunohistochemistry revealed that ICAM-1 is expressed in the amnion and chorion of the placenta [91][37], suggesting that it may be involved in the inflammatory process. Several investigations have reported that PE suppresses T cell activation and proliferation, and the hepatocytes showed increased levels of anti-inflammatory factors, including IL-5, granulocyte colony-stimulating factor (G-CSF), fractalkine, IL-10, and IL-13, and decreased levels of pro-inflammatory factors such as IFN-γ, IL-1β, IL-2, IL-3, IL-12, and TNF-α. Furthermore, decreases in soluble cd40 ligand (sCD40L), FMS-like tyrosine kinase 3 ligand (Flt 3L), and granulocyte macrophage-colony stimulating factor (GM-CSF) levels were also noticed [68][10]. It can be seen that PE could alleviate liver inflammation. However, further studies are needed to investigate the regulatory role of PE in signaling pathways.

45. PE Improves Liver Apoptosis and Autophagy

Apoptosis refers to the autonomous and orderly death of cells controlled by genes to maintain a stable internal environment, which is associated with various morphological and functional changes, such as cell shrinkage, chromatin agglutination, DNA fragmentation, apoptosome formation, and the expression levels of pro- and anti-apoptotic factors. Furthermore, autophagy is a process involving the phagocytosis of cytoplasmic proteins or organelles into vesicles and fusion with lysosomes to form autophagic lysosomes, which degrade the contents of the lysosomes, thereby realizing the metabolic needs of the cells themselves and leading to the renewal of some organelles. Thus, apoptosis and autophagy can reflect the situation in cell injury [92,93,94][38][39][40]. Annexin V is a phospholipid-binding protein and can specifically bind to the phosphatidylserine of early apoptotic cells, which is used in the measurement of cellular apoptosis [95][41]. Propidium iodide (PI) is a cell-impermeable dye that only stains dead cells or late apoptotic cells with damaged membranes [96][42]. Therefore, the combination of these two methods can better detect apoptotic cells. Moreover, cysteinyl aspartate specific proteinase-3 (caspase-3) was demonstrated to be crucial for poly(ADP-ribose)polymerase (PARP) cleavage and DNA fragmentation, which are regarded as apoptotic hallmarks [51][7].
PE exerts anti-apoptotic effects by reducing the DNA breaks or laddering and the number of apoptotic hepatocytes showing Annexin V- or PI-positive (Annexin V+/PI+) values, increasing B-cell lymphoma-2(Bcl-2) expression, and decreasing Bcl-2-associated X protein (Bax) and caspase-3 expression, and inhibiting the cleavage of PARP [51,75,76][7][17][18]. Similarly, PE increases the expression of anti-apoptotic factors Bcl-2 and Bcl-xl in liver endothelial cells [50][5]. LC3, which exists in the LC3-I and LC3-II forms, is a well-accepted autophagy marker involved in autophagosome formation [97][43]. PE inhibits drug-induced autophagy in HepG2 cells, and decreases LC3 conversion from LC3-I to LC3-II (the autophagosome marker) and the expression of autophagy-related factors, including DRAM, CHOP, P53, ATG8, cTSd, BEcN1, LAMP1, ATF4, and ATF6 [51][7]. Taken together, PE improves liver apoptosis and autophagy, but the effects on autophagy need further study.

56. PE Improves Liver Fibrosis and Collagen Deposition

Liver fibrosis represents a transitional and reversible stage between chronic hepatitis and cirrhosis, which is more often seen clinically in viral hepatitis or alcohol or fatty liver. It is characterized by the excessive accumulation of an extracellular matrix (ECM), primarily collagen (Col), within the liver that destroys the normal liver architecture [98][44]. Therefore, it is necessary to alleviate or prevent the process of liver fibrosis. Chemical drugs, physical damage, and nutritional disorders cause liver-inflammatory cell infiltration, ROS generation, and hepatocellular degeneration, further activating HSCs and transforming them into MFBs [98][44]. The activated HSCs and MFBs secrete a large number of a-SMA and various ECM, including col-I, col-III, and col-IV, which disrupts the homeostasis of collagen synthesis and degradation, resulting in the accumulation of ECM in the liver and the formation of fibrotic scars gradually [99][45]. This homeostasis depends on the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), which are the key factors in the degradation and remodeling of the ECM. TGF-β1 is a pivotal profibrogenic cytokine in liver fibrosis and an inhibitor of hepatocyte proliferation that can induce small mothers against decapentaplegic (Smad) 2/3 transcription and activate HSCs but is negatively regulated by Smad 7 [100,101,102,103][46][47][48][49]. In addition, the serum indexes of type III procollagen (PC-III), Col-IV, laminin (LN), and hyaluronidase (HA) can effectively reflect the condition of liver injury and fibrosis, and they are commonly used as clinical indicators to reflect liver fibrosis.
PE inhibits the TGF-β-induced expression of α-SMA, Col-I, Col-III, and Smad phosphorylation and activation to reduce collagen deposition and the fibrotic area, and it increases the activity and protein expression of MMP-9. In an in vitro study, PE decreased the expression of fibrosis-related genes, including actin alpha 2(Acta2), Col1a1, and TGF-β1 [50,65,68][5][6][10]. The hydroxyproline (Hyp) content could reflect collagen formation and indicate the amount and consistency of scar tissue [104][50]. A hepatoprotective agent with the placenta as the adjuvant can also reduce collagen deposition and the fibrotic area in the liver and decrease serum levels of HA, LN, PC-III, Col-IV, and Hyp. At the same time, the expression of fibrosis-related genes, including Col-I, Col-III, α-SMA, and TGF-β1, and the protein expression levels of Smad 2/3 and p-Smad 2/3 were decreased [63][3]. It could also be found that the gene and protein expression levels of Col-I and α-SMA decreased, and the activities of MMP-2 and MMP-9 increased, which can limit the synthesis and deposition of Col-I in the CP-MSC-transplanted liver [67][9]. Additionally, immunohistochemistry revealed that MMP-9, MMP-2, and MMP-12 were expressed in the amnion and chorion of the placenta, indicating that they have the potential to treat fibrosis [91][37]. In summary, PE can improve liver fibrosis and collagen deposition.

References

  1. Shimokobe, H.; Sumida, Y.; Tanaka, S.; Mori, K.; Kitamura, Y.; Fukumoto, K.; Kakutani, A.; Ohno, T.; Kanemasa, K.; Imai, S.; et al. Human placental extract treatment for non-alcoholic steatohepatitis non-responsive to lifestyle intervention: A pilot study. Hepatol. Res. 2015, 45, 1034–1040.
  2. Ghoneum, M.; El-Gerbed, M. Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses. Cancer Chemother. Pharmacol. 2021, 88, 961–971.
  3. Shen, B.; Deng, L.; Liu, Y.; Li, R.; Shen, C.; Liu, X.; Li, Y.; Yuan, H. Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl 4-induced liver fibrosis. Chin. Herb. Med. 2022, 14, 104–110.
  4. Nakayama, S.; Kodama, K.; Oguchi, K. A comparative study of human placenta hydrolysate (Laennec) by intravenous or subcutaneous injection on liver regeneration after partial hepatectomy in normal and CCl4-induced cirrhosis rats. Folia Pharmacol. Jpn. 1989, 94, 289–297.
  5. Yamauchi, A.; Kamiyoshi, A.; Koyama, T.; Iinuma, N.; Yamaguchi, S.; Miyazaki, H.; Hirano, E.; Kaku, T.; Shindo, T. Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells. Heliyon 2017, 3, e416–e433.
  6. Yamauchi, A.; Tone, T.; Toledo, A.D.; Igarashi, K.; Shindo, T. Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis. Biomed. Res. 2020, 41, 1–12.
  7. Bak, D.H.; Na, J.; Choi, M.J.; Lee, B.C.; Oh, C.T.; Kim, J.Y.; Han, H.J.; Kim, M.J.; Kim, T.H.; Kim, B.J. Antiapoptotic effects of human placental hydrolysate against hepatocyte toxicity in vivo and in vitro. Int. J. Mol. Med. 2018, 42, 2569–2583.
  8. Nakayama, S.; Yamauchi, M.; Oguchi, K. A comparative study of Laennec by intravenous or subcutaneous injection on CCl4-induced acute or chronic liver injury in rats. Folia Pharmacol. Jpn. 1989, 94, 137–144.
  9. Lee, M.-J.; Jung, J.; Na, K.-H.; Moon, J.S.; Lee, H.-J.; Kim, J.-H.; Kim, G.I.; Kwon, S.-W.; Hwang, S.-G.; Kim, G.J. Anti-fibrotic effect of chorionic plate-derived mesenchymal stem cells isolated from human placenta in a rat model of CCl4-injured liver: Potential application to the treatment of hepatic diseases. J. Cell. Biochem. 2010, 111, 1453–1463.
  10. Jung, J.; Lee, H.J.; Lee, J.M.; Na, K.H.; Hwang, S.G.; Kim, G.J. Placenta extract promote liver regeneration in CCl4-injured liver rat model. Int. Immunopharmacol. 2011, 11, 976–984.
  11. Hoekstra, L.T.; de Graaf, W.; Nibourg, G.A.; Heger, M.; Bennink, R.J.; Stieger, B.; van Gulik, T.M. Physiological and biochemical basis of clinical liver function tests: A review. Ann. Surg. 2013, 257, 27–36.
  12. Boland, B.S.; Dong, M.H.; Bettencourt, R.; Barrett-Connor, E.; Loomba, R. Association of serum bilirubin with aging and mortality. J. Clin. Exp. Hepatol. 2014, 4, 1–7.
  13. Bennink, R.J.; Tulchinsky, M.; de Graaf, W.; Kadry, Z.; van Gulik, T.M. Liver function testing with nuclear medicine techniques is coming of age. Semin. Nucl. Med. 2012, 42, 124–137.
  14. Azman, K.F.; Safdar, A.; Zakaria, R. D-galactose-induced liver aging model: Its underlying mechanisms and potential therapeutic interventions. Exp. Gerontol. 2021, 150, 111372–111393.
  15. Kim, H.J.; Kim, S.; Seo, J.S.; Bae, G.W.; Kim, K.N.; Kang, J.S. Effect of Single-Dose, Oral Enzymatic Porcine Placental Extract on Pharmacokinetics of Alcohol and Liver Function in Rats. Alcohol. Clin. Exp. Res. 2020, 44, 1018–1024.
  16. Moon, P.D.; Kim, K.Y.; Rew, K.H.; Kim, H.M.; Jeong, H.J. Anti-fatigue effects of porcine placenta and its amino acids in a behavioral test on mice. Can. J. Physiol. Pharmacol. 2014, 92, 937–944.
  17. Liu, K.X.; Kato, Y.; Kaku, T.; Sugiyama, Y. Human placental extract stimulates liver regeneration in rats. Biol. Pharm. Bull. 1998, 21, 44–49.
  18. Park, S.Y.; Kim, D.S.; Kang, S.A.; Park, S.M. Hepatoprotective Effects of Pig Placental Hydrolysates on Liver Damage-induced Rats by Injecting Carbon Tetrachloride. J. Appl. Biol. Chem. 2012, 55, 2040–2044.
  19. Maksimov, V.A.; Buntin, E.S.; Buntina, B.G.; Mysenkova, E.E.; Samartsev, K.N.; Vostokovf, G.V.; Burdenko, N.N. The influence of placental drug laennec on motor function of the biliary tract in patients with fatty degeneration of liver. Exp. Clin. Gastroenterol. 2016, 11, 100–103.
  20. Yamauchi, A.; Kamiyoshi, A.; Sakurai, T.; Miyazaki, H.; Hirano, E.; Lim, H.S.; Kaku, T.; Shindo, T. Development of a mouse iron overload-induced liver injury model and evaluation of the beneficial effects of placenta extract on iron metabolism. Heliyon 2019, 5, e1637–e1645.
  21. Shin, K.S.; Lee, H.J.; Jung, J.; Cha, D.H.; Kim, G.J. Culture and in vitro hepatogenic differentiation of placenta-derived stem cells, using placental extract as an alternative to serum. Cell Prolif. 2010, 43, 435–444.
  22. Wu, J.; Wang, C.; Liu, Q.; Yang, T.; Zhang, Q.; Peng, J.; Gao, Y.; Sun, H.; Kaku, T.; Liu, K. Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes. Eur. J. Pharmacol. 2008, 589, 299–305.
  23. Wu, J.; Yang, T.; Wang, C.; Liu, Q.; Yao, J.; Sun, H.; Kaku, T.; Liu, K.X. Laennec protects murine from concanavalin A-induced liver injury through inhibition of inflammatory reactions and hepatocyte apoptosis. Biol. Pharm. Bull. 2008, 31, 2040–2044.
  24. Sakamoto, K.; Tonooka, M.; Abe, K.; Usami, K.; Kasahara, T. Comparative studies on rat primary cultured and isolated hepatocytes in the evaluation of a therapeutic agents for liver disease. Jpn. J. Pharmacol. 1986, 41, 424–426.
  25. Togashi, S.I.; Takahashi, N.; Watanabe, S.; Ishiguro, A.; Fukui, T. Suppressive Effects of Uracil, Tyrosine, and Phenylalanine Contained in Human-Placenta Extract on Acute Ethanol-Induced Liver Injury in Mice. J. Health Sci. 2008, 46, 126–131.
  26. Liu, K.X.; Kato, Y.; Kaku, T.I.; Santa, T.; Imai, K.; Yagi, A.; Ishizu, T.; Sugiyama, Y. Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. J. Pharmacol. Exp. Ther. 2000, 294, 510–515.
  27. Togashi, S.I.; Takahashi, N.; Kubo, Y.; Shigihara, A.; Higashiyama, K.; Watanabe, S.; Fukui, T. Purification and Identification of Antioxidant Substances in Human-Placenta Extracts. J. Health Sci. 2008, 46, 117–125.
  28. Togashi, S.; Takahashi, N.; Iwama, M.; Watanabe, S.; Tamagawa, K.; Fukui, T. Antioxidative collagen-derived peptides in human-placenta extract. Placenta 2002, 23, 497–502.
  29. Watanabe, S.; Togashi, S.; Takahashi, N.; Fukui, T. L-tryptophan as an antioxidant in human placenta extract. J. Nutr. Sci. Vitaminol. 2002, 48, 36–39.
  30. Muller, F.L.; Song, W.; Liu, Y.; Chaudhuri, A.; Pieke-Dahl, S.; Strong, R.; Huang, T.T.; Epstein, C.J.; Roberts, L.N.; Csete, M.; et al. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic. Biol. Med. 2006, 40, 1993–2004.
  31. Yuan, L.; Kaplowitz, N. Glutathione in liver diseases and hepatotoxicity. Mol. Asp. Med. 2009, 30, 29–41.
  32. Di Pietro, C.; Öz, H.H.; Murray, T.S.; Bruscia, E.M. Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. Front. Pharmacol. 2020, 11, 1059–1076.
  33. Ross, D.; Siegel, D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch. Front. Physiol. 2017, 8, 595–604.
  34. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428–435.
  35. Park, S.Y.; Phark, S.; Lee, M.; Lim, J.Y.; Sul, D. Anti-oxidative and anti-inflammatory activities of placental extracts in benzo pyrene-exposed rats. Placenta 2010, 31, 873–879.
  36. Bui, T.M.; Wiesolek, H.L.; Sumagin, R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J. Leukoc. Biol. 2020, 108, 787–799.
  37. Bailo, M.; Soncini, M.; Vertua, E.; Signoroni, P.B.; Sanzone, S.; Lombardi, G.; Arienti, D.; Calamani, F.; Zatti, D.; Paul, P.; et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 2004, 78, 1439–1448.
  38. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516.
  39. D'Arcy, M.S. Cell death: A review of the major forms of apoptosis, necrosis and autophagy. Cell Biol. Int. 2019, 43, 582–592.
  40. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 741–752.
  41. Tzima, E.; Walker, J.H. Platelet annexin V: The ins and outs. Platelets 2000, 11, 245–251.
  42. Atale, N.; Gupta, S.; Yadav, U.C.; Rani, V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J. Microsc. 2014, 255, 7–19.
  43. Galluzzi, L.; Green, D.R. Autophagy-Independent Functions of the Autophagy Machinery. Cell 2019, 177, 1682–1699.
  44. Elpek, G.O. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J. Gastroenterol. 2014, 20, 7260–7276.
  45. Affo, S.; Yu, L.X.; Schwabe, R.F. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu. Rev. Pathol. 2017, 12, 153–186.
  46. Hermansyah, D.; Putra, A.; Muhar, A.M.; Retnaningsih; Wirastuti, K.; Dirja, B.T. Mesenchymal Stem Cells Suppress TGF-beta Release to Decrease alpha-SMA Expression in Ameliorating CCl4-Induced Liver Fibrosis. Med. Arch. 2021, 75, 16–22.
  47. Hu, Y.; He, J.; He, L.; Xu, B.; Wang, Q. Expression and function of Smad7 in autoimmune and inflammatory diseases. J. Mol. Med. 2021, 99, 1209–1220.
  48. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.; Renooij, W.; Murzilli, S.; Klomp, L.W.; Siersema, P.D.; Schipper, M.E.; Danese, S.; et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60, 463–472.
  49. Kaimori, A.; Potter, J.; Kaimori, J.Y.; Wang, C.; Mezey, E.; Koteish, A. Transforming Growth Factor-beta1 Induces an Epithelial-to-Mesenchymal Transition State in Mouse Hepatocytes In Vitro. J. Biol. Chem. 2007, 282, 22089–22101.
  50. Li, P.; Wu, G. Roles of dietary glycine, proline, and hydroxyproline in collagen synthesis and animal growth. Amino Acids 2018, 50, 29–38.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback